Oppenheimer & Co’s Ginkgo Bioworks DNA Stock Holding History

Oppenheimer & Co’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-250	Closed	-$116K	–	1506
2021 Q3	$116K	Buy	+250	New	+$122K	﹤0.01%	1441

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

SIG

Senator Investment Group New York $2.74B AUM 55.95% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Oppenheimer & Co's DNA Position: Q4 2021 in Review

Oppenheimer & Co sold out of Ginkgo Bioworks (DNA) in Q4 2021, closing a stake of 250 shares — an estimated $116K sold.

Oppenheimer & Co first reported a position in DNA in Q3 2021 and held it in 1 quarter. The position peaked at $116K in Q3 2021. 164 funds tracked by Wall St. Rank hold DNA as of Q4 2021.

Oppenheimer & Co reported no remaining Ginkgo Bioworks position as of Q4 2021 after selling out during the quarter.
Oppenheimer & Co sold 250 Ginkgo Bioworks shares in Q4 2021, an estimated $116K.
Oppenheimer & Co first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 1 quarter.
Oppenheimer & Co's Ginkgo Bioworks position peaked at $116K in Q3 2021.
164 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2021.

Based on Oppenheimer & Co's 13F filing for Q4 2021, filed 2 Feb 2022.